Medco

Roche made a splash last year with its repeated overtures to acquire genome sequencing firm Illumina, but for the most part, 2012 was a quiet year during which players in the life sciences industry took modest steps to increase their capabilities to advance personalized treatment

Illumina announced that Robert Epstein has joined its board of directors. Epstein formerly was chief R&D officer and president of Medco-UBC, and he was Medco’s chief medical officer for 13 years.

Third Rock Ventures has hired Felix Frueh as an entrepreneur-in-residence.

By Turna Ray
Two recently published pharmacogenetic analyses looking at the impact of CYP2D6 alleles on tamoxifen response found no evidence that patients who harbor these mutations fail to respond to the hormone therapy.

By Turna Ray

Canada's Center of Excellence in Personalized Medicine last week launched a personalized medicine portal developed in collaboration with DNA Direct.

By Monica Heger
One major hurdle in bringing next-generation sequencing into the clinic is how it will be received by payors and hospitals.

Pages

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.